Healthcare company Endo International has signed an agreement to acquire Auxilium Pharmaceuticals, for around $2.6bn.
Auxilium, which produces products in the men’s healthcare area, has expanded its product portfolio to orthopedics, dermatology and other therapeutic areas.
Endo International president and CEO Rajiv De Silva said the company intends to leverage Auxilium’s leading presence in men’s health, and also firm’s R&D capabilities and financial resources to accelerate the growth of Xiaflex.
Currently, Auxilium has 12 approved products and markets edex (alprostadil for injection), an injectable treatment for erectile dysfunction and ErecAid, a device for aiding erectile dysfunction.
It also markets Testopel (testosterone pellets), an implantable testosterone replacement therapy, and Xiaflex for the treatment of Peyronie’s disease, as well as Testim for the topical treatment of hypogonadism.
Endo develops and markets pharmaceutical, generic and device products through its operating companies.